Autophagy in rare (nonlysosomal) neurodegenerative diseases by Zatyka, Malgorzata et al.
 
 
University of Birmingham
Autophagy in rare (nonlysosomal)
neurodegenerative diseases
Zatyka, Malgorzata; Sarkar, Sovan; Barrett, Timothy
DOI:
10.1016/j.jmb.2020.02.012
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Zatyka, M, Sarkar, S & Barrett, T 2020, 'Autophagy in rare (nonlysosomal) neurodegenerative diseases', Journal
of Molecular Biology, vol. 432, no. 8, pp. 2735-2753. https://doi.org/10.1016/j.jmb.2020.02.012
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
ReviewNeurodegenerat
Malgorzata Zatyka1, Sovan Sarkar1 and0022-2836/© 2020 The A
creativecommons.org/licenAutophagy in Rare (NonLysosomal)
ive DiseasesTimothy Barrett 1, 2
1 - Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15
2TT, UK
2 - Department of Endocrinology, Birmingham Women's and Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UKCorrespondence to Timothy Barrett: Room WX1.37, Level 1, IBR West Extension, Vincent Drive, University of
Birmingham, College of Medical and Dental Sciences, Institute of Cancer and Genomic Sciences, Edgbaston,
Birmingham, B15 2TT, UK. Fax: þ44 (0) 121 414 4486. t.g.barrett@bham.ac.uk
https://doi.org/10.1016/j.jmb.2020.02.012
Edited by Manolis FantoAbstract
Neurodegenerative diseases (NDDs) comprise conditions with impaired neuronal function and loss and may
be associated with a build-up of aggregated proteins with altered physicochemical properties (misfolded
proteins). There are many disorders, and causes include gene mutations, infections, or exposure to toxins.
The autophagy pathway is involved in the removal of unwanted proteins and organelles through lysosomes.
While lysosomal storage disorders have been described for many years, it is now recognised that
perturbations of the autophagy pathway itself can also lead to neurodegenerative disease. These include
monogenic disorders of key proteins involved in the autophagy pathway, and disorders within pathways that
critically control autophagy through monitoring of the supply of nutrients (mTORC1 pathway) or of energy
supply in cells (AMPK pathway). This review focuses on childhood-onset neurodegenerative disorders with
perturbed autophagy, due to defects in the autophagy pathway, or in upstream signalling via mTORC1 and
AMPK. The review first provides a short description of autophagy, as related to neurons. It then examines the
extended role of autophagy in neuronal function, plasticity, and memory. There follows a description of each
step of the autophagy pathway in greater detail, illustrated with examples of diseases grouped by the stage of
their perturbation of the pathway. Each disease is accompanied by a short clinical description, to illustrate the
diversity but also the overlap of symptoms caused by perturbation of key proteins necessary for the proper
functioning of autophagy. Finally, there is a consideration of current challenges that need addressing for future
therapeutic advances.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Neurodegenerative diseases (NDDs) comprise
conditions with impaired neuronal function and loss
and may be associated with a build-up of aggregated
proteins with altered physicochemical properties
(misfolded proteins). It has been estimated that
almost 30% of newly translated proteins in the cell
are not folded correctly, even under healthy condi-
tions [1]. The classic pattern of a neurodegenerative
disorder in childhood is regression and progressive
loss of neuronal function affecting speech, vision,
hearing, or movement. It may be accompanied by
seizures and cognitive decline [2]. There are manyuthor(s). Published by Elsevier Ltd. This
ses/by/4.0/).disorders that can be caused by monogenic defects,
infections, or exposure to toxic substances. Anato-
mically, they may involve the neuronal cell bodies,
both unmyelinated and myelinated axons, dendrites,
and glial cells.
The realisation that many NDDs involve abnormal
protein deposition in the brain led to discoveries,
such as the role of the unfolded protein response [3],
and protein elimination pathways, such as the
ubiquitin-proteasome pathway and the autophagy
pathway [4]. These pathways may interact with other
pathways, such as mitochondrial energy metabo-
lism, ion homeostasis, and intermediary metabolic
pathways, to damage neurons. DNA damage,
is an open access article under the CC BY license (http://
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2736 Autophagy in neurodegenerationneuroinflammatory processes, and disruption of
cellular/axonal transport may also result in the
toxicity of NDD-related proteins [5].
The role of the autophagy pathway in neurode-
generative diseases has received prominence as a
route for clearance of cytosolic, aggregate-prone
proteins, and organelle degradation through lyso-
somes [5]. Lysosomes function as the primary
digestive units within cells. Their function is to
break down complex components into simpler
ones. Each cell has hundreds of lysosomes that
degrade substrates, such as misfolded proteins and
protein aggregates. When this process does not takeTable 1. List of genes, associated proteins, and childhood-on
autophagy, ordered by the likely position of each main defec
published in UniProt www.uniprot.org.
Affected stage of the autophagy
pathway
Gene
Initiation signals to the
ULK1 complex: the
mTOR pathway
TSC1, TSC2 Hamartin, T
Initiation signals to the ULK1
complex: the AMPK pathway
e.g. ND5 NADH-
ubiquinone
chain 5
Phagophore nucleation e.g. ATXN3 Ataxin-3
Early phagophore formation WDR45 WD repeat
phosphoino
protein 4 (W
Early phagophore formation e.g. C19orf12 Protein C19
Phagophore membrane elongation ATG5 Autophagy
Phagophore membrane elongation TECPR2 Tectonin be
repeat-con
Phagophore membrane elongation AP4S1 AP-4 comp
1
Phagophore membrane elongation WDR45 WD repeat
phosphoino
protein 4 (W
Autophagosome formation EPM2A, EPM2B Laforin, Ma
Cargo recognition and
delivery to degradation
SQSTM1/P62 Sequestoso
Cargo recognition and
delivery to degradation
IT15 Huntingtin
Autophagosome maturation VPS11 Vacuolar
VPS11
Autophagosome maturation S P G 1 1 ,
ZFYVE26
Spatacsin,
domain-con
protein 26 (
Autophagosome/lysosome fusion EPG5 Ectopic p-g
homologue
Regulation of lysosome function CCT5 Chaperonin
T-complex
subunit eps
Regulation of lysosome function SNX14 Sorting nex
Lysosomal/
autolysosomal acidification
DNM2 Dynamin 2
Transport of autolysosome cargoes DYNC1H1 Dynein cyto
heavy chaiplace or is overwhelmed, a progressive accumula-
tion of undigested macromolecules can occur pre-
dominantly in the cytosol, and even in the lysosomes
causing lysosomal storage disorders (LSDs). LSDs
are a group of about 60 different diseases, which are
inborn errors of metabolism, resulting in the absence
or deficiency of an enzyme, leading to the inap-
propriate build-up and storage of material in various
cells of the body.
However, it is now recognised that perturbations of
the autophagy pathway itself, can also lead to a
neurodegenerative disease beyond lysosomal sto-
rage disorders. These include single-gene disordersset neurodegenerative diseases associated with impaired
t in the autophagy pathway. Gene and protein names as
Protein Disease
uberin Tuberous Sclerosis
oxidoreductase
Leigh encephalopathy
Spinocerebellar ataxia type 3
domain
sitide-interacting
IPI4)
Beta-propeller protein-associated
neurodegeneration (BPAN, NBIA, SENDA)
orf12 Neurodegeneration with brain
iron accumulation (NBIA) (mitochondrial
membrane protein-associated
neurodegeneration (MPAN), hereditary
spastic paraplegia (SPG43))
protein 5 Hereditary childhood ataxia
ta-propeller
taining protein 2
Hereditary spastic paraplegia (SPG49)
lex subunit sigma- Hereditary spastic paraplegia (SPG47,
SPG52)
domain
sitide-interacting
IPI4)
Beta-propeller protein-associated
neurodegeneration (BPAN, NBIA, SENDA)
lin Lafora disease
me-1 Childhood-onset neurodegeneration
Huntington disease
sorting protein Leucoencephalopathy
Zinc finger FYVE
taining
spastizin)
Hereditary spastic paraplegia
(SPG11, SPG15 (SPG15 also
interacts with Beclin1)
ranules protein 5 VICI syndrome
-containing
protein 1
ilon
Hereditary spastic paraplegia
in-14 Ataxia
Charcot Marie Tooth disease
plasmic 1
n 1
Spinal muscular atrophy
2737Autophagy in neurodegenerationof components in the autophagy pathway and
disorders in pathways that critically control autop-
hagy through the monitoring of nutrient or amino acid
supply (mTORC1 pathway) or cellular ATP levels
(AMPK pathway). This review will focus on child-
hood-onset neurodegenerative disorders with per-
turbed autophagy, due to defects in the autophagy
pathway, or in upstream signalling via mTORC1 and
AMPK. The review will first provide a brief overview
of autophagy, with particular reference to neurons. It
will then examine the extended role of autophagy in
neuronal function, plasticity, and memory. There
follows a description of each step of the autophagy
pathway in greater detail, illustrated with examples of
diseases grouped by the stage of their perturbation
of the pathway (Table 1). Each disease is accom-
panied by a clinical description, to illustrate the
diversity but also the overlap of symptoms caused by
perturbation of different stages of the autophagy
pathway. Finally, there is a consideration of current
challenges that need addressing for future thera-
peutic advances.Overview of Autophagy
Autophagy is a cellular homeostatic catabolic
pathway, which functions as a quality control
mechanism to clear old proteins, unwanted protein
aggregates, and damaged organelles; and to
recover nutrients by the degradation of these
proteins and organelles during stress conditions. A
basal level of autophagy is always present in all
cells, but for fulfiling its role in nutrient recovery, it is
induced under stress conditions, such as starvation
or energy depletion. There are three forms of
autophagy with different mechanisms of cargo
delivery, chaperone-mediated autophagy (CMA),
microautophagy, and macroautophagy [6,7]. Cha-
perone-mediated autophagy selectively recognises
proteins with a KFERQ-like amino acid motif and
uses the chaperone proteins and Lysosome Asso-
ciated Membrane Protein (LAMP2A) as a receptor,
to deliver proteins for lysosomal degradation. Micro-
autophagy delivers cargo directly to lysosomes by
inward invagination of the lysosomal membrane.
Macroautophagy uses double-membrane vesicles
(autophagosomes) to engulf the cargo. Autophago-
somes undergo multistage maturation processes
and eventually fuse with lysosomes, releasing their
cargo for degradation. Although autophagy occurs in
almost all cell types, there is cell type/tissue-specific
regulation.
Macroautophagy is generally understood as a
nonspecific degradation pathway (“bulk autophagy”)
where a mixed cargo is engulfed and processed.
There are also cargo-specific forms of autophagy,where a specific cargo is targeted, such as mito-
phagy (degradation of mitochondria; relevant to
neurodegeneration [8]), ER-phagy, where the autop-
hagosomes selectively include ER membranes [9],
pexophagy and ribophagy for specific degradation of
peroxisomes and ribosomes respectively [10,11],
aggrephagy (relevant to neurodegeneration) targets
protein aggregates [12], lipophagy for lipid droplets
[13], and xenophagy degrades intracellular patho-
gens [6,14]. The selectivity is achieved by receptors
with domains recognising the label on the cargo and
domains recognising ATG8 family members (like
LC3II) on autophagosome membranes. For cargo to
be recognised by the receptors, it is modified, most
commonly by ubiquitination. Ubiquitinated cargo is
recognised by ubiquitin-binding receptors (adaptors)
like p62/SQSTM1, NBR1, OPTN (optineurin), or
NDP52. Other modifications are recognised by
ubiquitin independent receptors like NIX, BNIP3,
FUNDC1, RETREG1/FAM134B, and galectin 8 [15].
Macroautophagy (which in this review is referred
to as “autophagy”) will be the main form of
autophagy considered in this review as its impair-
ment resul ts in many di f ferent forms of
neurodegeneration.Upstream Pathways Required to Initiate
Autophagy
In cells, there exists a certain basal constitutive
level of autophagy, but the process is also strictly
regulated by environmental and intracellular signal-
ling. Nutrient and energy depletion results in the
activation of autophagy via two principal upstream
pathways, mammalian target of rapamycin
(mTORC1) [16] and AMP-activated protein kinase
(AMPK) [17]. Under the fed conditions, autophagy is
inhibited by active mTORC1 kinase complex; how-
ever, when nutrient deprivation is sensed, mTORC1
becomes inactive and mTORC1 sites on ULK1
(unc51-like autophagy activating kinase 1) become
dephosphorylated, removing its inhibition of ULK1
complex.
Autophagy is also induced by energy depletion
sensed by the AMPK pathway, which detects the
ATP deficit by sensing changes in the ATP to AMP
ratio. AMPK activates autophagy directly by phos-
phorylation of ULK1, which activates the ULK1
complex, or indirectly via inhibition of mTORC1
[18,19].
A further level of autophagy regulation takes place
during autophagy and lysosomal gene transcription.
Among transcription factors involved, the key role is
played by TFEB (Transcription Factor EB), which
regulates expression of “coordinated lysosomal
expression and regulation network of genes”
2738 Autophagy in neurodegeneration(CLEAR) [20,21]. The localisation and activity of
TFEB are both regulated by mTOR-mediated phos-
phorylation: during the fed state, TFEB is negatively
regulated by mTORC1 (phosphorylated) and is
located in lysosomal membranes. After mTORC1
inactivation, TFEB is dephosphorylated, released
from lysosomal membranes, and translocated to the
nucleus where it drives transcription of target genes.
A related transcription factor, MITF, performs an
analogous role in melanocytes by binding the
CLEAR-box elements of lysosomal and autophago-
somal genes.1. INITIATION 
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Fig. 1. Autophagy pathway overview, with childhood-onset
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Inhibition of mTORC1 results in autophagy initia-
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ULK1 kinase complex proteins (ULK1, ATG13,
FIP200, ATG101) leading to activation of ULK1
complex and translocation to specific sites on ER
membranes called omegasomes, the platforms for
phagophore formation [22]. ULK1 complex recruits
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neurodegeneration with brain iron accumulation. Inhibitory
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2739Autophagy in neurodegenerationPIK3R4/VPS15, Beclin1, ATG14, and others) to
these subdomains. This leads to the production of
phosphatidylinositol 3-phosphate (PI3P) and to
recruitment of PIP3-binding proteins DFCP1 (double
FYVE domain containing protein), and WIPI (WD40
repeat protein interacting with phosphoinositides)
family proteins. This directs localisation of ATG12-
ATG5-ATG16L complex to the nucleation site to
perform phagophore elongation (Fig. 1).
The origin of membranes for autophagosome
formation has been extensively investigated, and
many organelles have been proposed as membrane
sources, as well as de novo assembly. Endoplasmic
reticulum (ER), Golgi, lysosomes, mitochondria, and
plasma membrane were all proposed as sources
[23,24]. Recent studies suggest that ER contact
sites with other organelles become the sites for
autophagosome biogenesis [25]. Among them, the
Mitochondrial Associated Membrane (MAM), a dis-
tinct domain of ERemitochondria contact sites, was
proposed as a place for autophagosome biogenesis
[26].
The elongation of phagophores requires lipidation
of ATG8 family proteins, including microtubule-
associated protein light chain 3 (LC3), to produce
LC3II. Before lipidation can take place, LC3 has to
be cleaved by cysteine protease ATG4 at its C-
terminus, exposing a glycine residue (LC3I form).
This is required for LC3-I conjugation to phosphati-
dylethanoloamine (PE). Lipidated LC3-II (and its
family members LC3A, B, C, and GABARAP)
become associated with the phagophore membrane
and transmembrane protein ATG9 is recruited to
further support elongation. ATG9 localises to trans-
Golgi network and endosomes and is understood to
supply lipid bilayers for phagophore elongation and
closure to create the autophagosome [27e30].
The fusion stage with lysosomes to form autolyso-
somes requires transportation of autophagosomes,
formed anywhere in the cell, along microtubules to
perinuclear areas of the cell where lysosomes are
present by dynein-dependent retrograde transport.
The maturation of autophagosomes to autolyso-
somes depends on the coordinated action of ATG8
family members, tethering factors, Rab GTPases,
and SNARE proteins (Synaptic soluble N-ethylma-
leimide-sensitive factor attachment protein receptor)
to mediate fusion of autophagosomes with endoly-
sosomal vesicles [23,24,31]. After fusion, the lyso-
somal hydrolases degrade the cargo, and the basic
building block molecules are recycled to the cyto-
plasm for reuse, as well as for lysosomal compo-
nents [32].Autophagy in Neurons
Autophagy is particularly important in neurons as
they are long-lived terminally differentiated cells,which cannot dilute the accumulated damaged
proteins and organelles by cell division. They
operate under high metabolic demand, due to
repetitive stimulation to process and transmit infor-
mation, making them uniquely prone to oxidative
stress and organelle damage.
The removal of damaged organelles and mis-
folded or aggregated proteins is important during
both neuronal development and during lifelong
maintenance of neuronal health. The autophagy
pathway has to be adapted to specific demands in
neurons due to their highly specialised structure and
function: long axons and branched dendrites pro-
truding from the neuronal body, the primary place
where biological processes take place. This brings
the problem of trafficking over long distances and
compartmentalisation. These problems are solved
by a specific spatial organisation of autophagy in
neurons with different forms of autophagy taking
place in different subcellular compartments [33,34].
Autophagosome formation takes place mainly in
distal axons, is constitutive, and autophagosomes
are transported to soma by retrograde transport
during which they fuse with lysosomes. They are
rarely detected in dendrites and soma [35,36].
However, dendritic autophagy modulates neuronal
excitation and inhibition [37] and dendritic branching
[38].Autophagy Plays a Vital Role in the
Maintenance of Neuronal Homeostasis
and Defects in Autophagy Genes Result
in Neurodegeneration in Animal Models
Autophagy is crucial to maintain neuronal home-
ostasis, and its impairment can lead to neurodegen-
eration. Ubiquitous deletions of core autophagy
genes result in neonatal and embryonic lethality;
therefore, nervous system-specific knockout mice
were used to study the role of autophagy in neurons.
The knockdown of autophagy genes in neurons in
animal and cellular models results in protein accu-
mulation and neuronal cell loss. Conditional knock-
down of Atg5 in mouse neural precursors led to the
loss of Purkinje and cerebral cortical pyramidal cells
and axonal swelling in various parts of the brain [39].
Knockdown of Atg7 in the central nervous system of
mice resulted in behavioural changes and impair-
ment of coordination. The animals displayed abnor-
mal limb-clasping reflexes and died by 7 months of
age. A massive loss of neurons was observed in the
cerebral and cerebellar cortices, and there was a
build-up of polyubiquitinated proteins in the form of
inclusion bodies. The number and size of the
inclusion bodies increased as the animals grew
older [40]. Moreover, conditional Atg7 knockdown in
Purkinje cells in mice led to neuronal and axonal
2740 Autophagy in neurodegenerationdystrophy, degeneration of axon terminals, and cell
death [41]. As another example, neuron-specific
knockdown of FIP200 in mice caused the loss of
Purkinje cells and granular cells, spongiosis in the
cerebellar white matter, axonal and dendritic degen-
eration in Purkinje cells, axonal swelling and
accumulation of ubiquitin-positive aggregates [42].Role of Autophagy in Neuronal Activity,
Plasticity and Memory
In addition to its clearing function in homeostasis
maintenance, autophagy recently emerged as a
regulator of neuronal activity, plasticity and memory.
Synaptic plasticity is achieved by structural and
functional modifications of synapses, which involve
tight regulation of both protein synthesis and
degradation in a spatial and temporal manner [43].
The involvement of the ubiquitin-proteosome system
(UPS) in this remodelling is well known, but
autophagy has emerged as another important
player; synaptic proteins and vesicles, postsynaptic
receptors and organelles-like mitochondria are
carried by autophagosomes at synapses and are
degraded by autophagy [44]. Postsynaptic receptors
GABAA and AMPA were reported to be degraded by
autophagy [37,45] suggesting that autophagy may
regulate the balance of neuronal excitation and
inhibition, essential for synaptic plasticity and brain
function [43]. Presynaptic autophagy was shown to
modulate synaptic vesicle numbers and neurotrans-
mission [46]. Mitophagy at the synapses may also be
important because synaptic activities demand
energy and proper calcium buffering capacity
[43,47,48]. Postsynaptic scaffolds PSD-95, PICK1,
and SHANK3 were also shown to constitute autop-
hagosome cargo [49]. In addition, several synaptic
proteins were shown to modulate the rate of
autophagosome biogenesis. The presynaptic pro-
teins Endofilin A (Endo A) and Synaptojanin-1
(Synj1) were found to promote synaptic autophagy
[50,51], while active zone protein Bassoon inhibits
presynaptic machinery by inhibiting ATG5 [52].
Autophagy involvement in the regulation of synaptic
plasticity indicates that autophagy is required for
memory formation, and studies showed that autop-
hagy could reverse the age-related memory decline
[53].Role of Autophagy in
Neurodevelopment
Autophagy is also an important regulator of
neurodevelopment by negatively regulating axon
outgrowth and positively regulating synaptic forma-
tion [33,34]. It modulates dendritic branching (arbor-
isation) by facilitating organelle and membraneturnover during branch retraction and extension
[38] and/or by decreasing levels of Highwire,
a ubiquitin ligase complex, which promotes arbor-
isation, and is needed for normal synaptic morphol-
ogy during development (and axonal regeneration
after injury) [54]. It can also regulate dendritic
degeneration [55]. During brain development in
mouse embryos increased Atg5 expression is
observed at the time of cortical neuronal precursors
(NPC) differentiation. In mice with Atg5 deficiency in
the cortex - decreased differentiation of NPC and
increased neuronal proliferation takes place. This
results in impairment of the morphology of cortical
neurons [56]. The loss of autophagy due to the
deletion of the essential autophagy gene Atg7 in
proopiomelanocortin neurons perturbs axon growth
[57], while autophagy deficiency in microglia leads to
impairment of synaptic pruning and causes social
and behavioural defects in mice [58,59].
In summary autophagy has a vital role in neurons
by maintaining neuronal homeostasis, protecting
from neurodegeneration, and regulating neural
activity, plasticity, and neurodevelopment.Diseases in Upstream Pathways
Controlling Autophagy-the mTOR
Pathway
Two pathways that critically control autophagy are
the mTORC1 pathway that monitors the availability
of nutrients to cells; and the AMPK pathway that
monitors energy levels (ATP) in cells [6]. These
pathways act proximally in the autophagy pathway,
at the UNC51-like kinase (ULK) 1/2 complex. This
complex is made up of ULK1 (homologue ULK2),
ATG13, ATG101, and FAK family kinase-interacting
protein (FIP200). The interaction between ULK1 and
ATG13 relies on the regulation by mTOR and AMPK,
of ATG13 phosphorylation [60]. When nutrients are
in plentiful supply, mTOR phosphorylates ATG13.
This inactivates the ULK1 complex and reduces
autophagic flux. In contrast, under starvation condi-
tions, the ULK1 complex becomes active as ATG13
is dephosphorylated. The activation of the ULK1
complex and its interaction with AMPK is also
dependent on the phosphorylation of ULK1, which
is mediated by mTOR. Once ULK1 is activated,
FIP200 is phosphorylated. The phosphorylation of
FIP200 activates the VPS34 complex, the next step
in the autophagy pathway.
Mammalian Target of Rapamycin (mTOR) com-
plex 1 (mTORC1) is a serine threonine kinase,
ubiquitously expressed, and a master regulator of
cell growth, cellular metabolism, and autophagy.
mTORC1 facilitates cellular anabolic processes.
However, mTORC1 also inhibits catabolism, includ-
ing the autophagy pathway. Physiological states that
2741Autophagy in neurodegenerationinduce autophagy, including nutrient deprivation,
reduce the activity of mTORC1. A mediator of the
effects of mTORC1 is TFEB; this regulates autop-
hagy through transcription, the UKL1/2, and VPS34
complexes (see Fig. 1). The importance of this
pathway is that genetic defects in the mTOR
pathway impact on autophagy. In addition, many
mTORC1 inhibitor compounds, including drugs
already licenced for other conditions, act as autop-
hagy inducers, and some are already used clinically.
An illustrative example of a genetic defect in the
mTOR pathway is tuberous sclerosis.Tuberous Sclerosis
Tuberous Sclerosis, also known as Tuberous
Sclerosis Complex (TSC) is a rare genetic disorder
caused by germline inactivating mutations in either
the TSC1 or TSC2 genes. Affected persons manifest
with neurological disease (seizures, intellectual
impairment, autism), tumours, which can occur in
the brain, heart, skin, and kidney, and pulmonary
lymphangioleiomyomatosis. TSC is associated with
neurodegeneration of selected neurons [61], and so
is included in this review. The tumours are mainly
noncancerous (benign), the condition is present from
birth, and symptoms usually become apparent in
childhood. The tumours can cause a range of
additional health problems, including epilepsy, learn-
ing difficulties, behaviour problems, including autistic
spectrum disorder, and skin problems, such as
patches of light-coloured or thickened skin, or
acne-like spots on the face. Brain lesions include
the benign cerebral cortical lesions called ‘tubers’,
nodules, tumours, white matter lesions, hydroce-
phalus, and hemimegalencephaly. There is limited
understanding of the cerebellar pathology; however,
a mouse model has been described, with a selective
Purkinje cell deletion of Tsc2 [61]. The abnormalities
included a gradual enlargement of the size of the
Purkinje cells and apoptotic cell death. Subsequent
post-mortem analysis of human cerebellum samples
from TSC patients showed Purkinje cell loss by 50%.
TSC thus causes significant morbidity in children
and adults.
TSC is inherited as an autosomal dominant
condition. The disease is due to germline mutations
in TSC1 or TSC2 [62,63]. The product of the TSC1
gene, is an interacting partner with tuberin (encoded
by the TSC2 gene, forming a heterodimer [64,65].
The TSC complex is a regulator of the rapamycin-
sensitive form of the mTOR kinase (mTORC1) [66].
It is likely that dysregulation of mTORC1 is the route
by which the pathogenesis in TSC is mediated. In
health, the TSC complex inhibits mTORC1 kinase
via tuberin’s GTPase activating domain, mediated
by the Rab-like protein Rheb [67,68]. However, with
a loss of function of the TSC complex, mTORC1 isactivated, and stimulates cap-dependent protein
synthesis, cell growth, and proliferation, via phos-
phorylation of key intermediaries. These include S6
kinase, ribosomal protein S6, and 4EBP1.
In terms of autophagy, mTOR also regulates the
phosphorylation status of ATG13, part of the
UNC51-like kinase (ULK)1/2 complex. The ULK1-
ATG13 interaction modulates autophagy through a
complex set of conjugation interactions at the
initiation stage of the autophagy pathway. In TSC,
mTOR phosphorylates ATG13; this inhibits its
interaction with ULK1. The result of this is that the
complex is inactivated so that further activation of the
autophagy pathway is inhibited. In an elegant series
of experiments, Parkhito et al. showed that cells
lacking TSC2 have low levels of autophagy under
basal and cell stress conditions [69]. The survival of
Tsc2-deficient tumour cells was dependent on
autophagy induction, thus showing the therapeutic
potential of autophagy inducers in TSC. Since the
first human studies of the mTOR inhibitor Rapamycin
to treat astrocytomas in TSC [70], the mTOR
inhibitor Everolimus has been licensed by the UK
MHRA and US FDA to treat aspects of TSC,
including refractory seizures.Diseases in Upstream Pathways
Controlling Autophagy-the AMPK
Pathway
AMPK can sense energy levels inside cells, in the
form of adenosine nucleotides. AMPK is activated
when there is a reduction in ATP levels in associa-
tion with rising levels of AMP and ADP [71]. AMPK
has an overall effect of promoting catabolism,
including autophagy and inhibiting anabolism. This
has the effect of generating ATP. In conditions where
nutrients are scarce, AMPK acts as a metabolic
checkpoint inhibiting cell growth. This is partly
through suppression of mTORC1, via direct phos-
phorylation of TSC2, but also directly through
phosphorylation of the mTORC subunit Raptor
(regulatory associated protein of mTOR). This
inhibits the mTORC1 kinase complex from phos-
phorylating its target proteins [72]. The effect of this
on ULK1 is to remove its inhibition by mTORC1. In
addition to its role in inhibiting cell growth and
increasing autophagy through suppression of
mTORC1, AMPK can increase autophagy through
direct phosphorylation of ULK1. Thus AMPK is able
to promote autophagy through dual routes of both
direct activations of ULK1 and through modifying the
mTORC1-mediated inhibition of ULK171. AMPK can
also trigger the removal of dysfunctional mitochon-
dria through the promotion of mitophagy, mediated
via ULK1, and can also support the generation of
new mitochondria. While autophagy is a survival
2742 Autophagy in neurodegenerationresponse to starvation conditions, which inhibit
mTOR kinase, diseases that reduce the production
of ATP via oxidative phosphorylation can impair
autophagy [73]. This report showed elegantly that
genetic defects in complex 1 of the respiratory chain
were able to suppress mTOR inhibitor-mediated
autophagy; on the other hand, interventions that
increased mitochondrial function were able to
promote autophagy. An example of a respiratory
complex 1 defect is Leigh encephalopathy.Leigh Encephalopathy
Leigh syndrome is a progressive neurodegenera-
tive disease affecting mostly infants. It is charac-
terised by progressive loss of mental and movement
abilities (psychomotor regression) and usually
results in death within 2e3 years, often due to
respiratory failure. The presentation can be with
vomiting, diarrhoea, and difficulty swallowing. These
problems cause growth failure and failure to thrive
and may cause muscle and movement disorders.
These may include weak muscle tone (hypotonia),
involuntary muscle contractions (dystonia), and
balance problems (ataxia). Sensory deficits causing
loss of sensation may also be apparent. Other
features may include weakness of eye muscles,
rapid involuntary eye movements (nystagmus), optic
atrophy, central respiratory failure, hypertrophic
cardiomyopathy, and lactic acidosis. It is charac-
terised by bilateral lesions in the brainstem and/or
basal ganglia, with an average age of death of 6e7
years [74], and associated with defects in mitochon-
drial energy production through the oxidative phos-
phorylation pathway. Mutations in genes encoding
subunits of complex 1 of the respiratory chain are
commonly reported [75]. This results in defective
production of ATP through the oxidative phosphor-
ylation pathway. In normal circumstances, AMPK
senses defective production of ATP and promotes
autophagy in response. This is indeed the case in
patients with Leigh syndrome of late-onset and
milder disease severity [76]. However, in a geno-
type-phenotype correlation study, cells from a
patient with the most severe, early-onset disease
bearing a mutation in the ND5 gene (13513G > A)
was unable to increase autophagic flux in response
to reduced ATP production. Currently there are no
effective therapies for this devastating condition.
There are mouse models of Leigh syndrome,
deficient in the mitochondrial respiratory chain
subunit Ndufs2 (NADH dehydrogenase ubiquinone)
[2]. Critically, rapamycin, a specific mTOR inhibitor,
enhanced the survival and attenuated disease
progression, including delaying the onset of neuro-
logical symptoms. This was thought to be through ametabolic shift towards amino acid catabolism and
away from glycolysis, alleviating the build-up of
glycolytic intermediates. This does offer the hope
that therapies to increase catabolism, including
autophagic flux, may be a treatment option in
diseases, such as Leigh syndrome, where there is
an ATP supply defect, and genotype-phenotype
correlation studies support this approach.Diseases Affecting Phagophore
Nucleation: the PI3KC3 Complex 1
The VPS34 complex is recruited to the autophago-
some formation site by the activated ULK1 complex
through the phosphorylation of FIP200. The VPS34
complex is made up of the following components:
phosphatidylinositol 3-kinase class 3 (VPS34
kinase), Beclin-1, and phosphatidylinositol 3-kinase
regulatory subunit 4 (VPS15). These components,
once in a complex, form an association with ATG14.
Toxic protein aggregates can competitively bind to
Beclin-1, preventing phagophore initiation and inhi-
biting autophagic flux. There are a number of different
proteins that contain polyglutamine tract (polyQ)
domains, which can interact with Beclin-1 [77].
Diseases, such as Huntington’s (huntingtin protein)
and spinocerebellar ataxia 3 (ataxin-3 protein), are
caused in part by expanded polyQ tracts, that
compete for interaction with Beclin-1 in a length-
dependent fashion: the longer the polyQ tract, the
more impairment of autophagy initiation. One exam-
ple of a disease forwhich pathogenesis ismediated in
part by inhibition of phagophore initiation is spinocer-
ebellar ataxia type 3.Spinocerebellar Ataxia Type 3 (SCA3)
Also termed Machado-Joseph disease, this dis-
ease is characterised by progressive movement
disorders, including a gradual loss of balance and
falls. There are five types, of which type 1 affects
13% and includes onset in childhood [78]. Its
progress can be rapid, with severe rigidity and
dystonia. It is caused by mutations in ATXN3,
encoding Ataxin-3, an enzyme in the ubiquitin-
proteasome pathway for removing damaged pro-
teins. The de-ubiquitinating enzyme Ataxin-3 is
widely expressed in the brain and can interact with
Beclin-1 via its polyglutamine tract (polyQ) domain,
protecting it from proteasome-mediated degrada-
tion, therefore enabling autophagy. This function for
wild type ataxin-3 is abrogated by competing longer
polyQ tracts in disease proteins. However, there is
another deleterious effect of longer polyQ tracts on
ataxin-3 itself, leading to misfolding and clustering
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particularly susceptible to these aggregates, leading
to cell loss and the characteristic symptoms.Diseases Affecting Early
Autophagosome Formation
The VPS34 complex is responsible for phospha-
tidylinositol 3-phosphate (PI3P) being produced.
This is done in a part of the ER known as the
omegasome [28]. Omegasomes are membrane
compartments enriched in PI3P and serve as plat-
forms for the formation of at least some autophago-
somes [79]. These have also been termed
‘autophagosome initiation sites’, and they attract
proteins that can bind PI3P. PI3P attracts other
proteins that mediate its actions. These include WD
repeat domain phosphoinositide-interacting proteins
(WIPIs) WIPI12 and zinc finger FYVE domain-
containing protein 1 (DFCP1). These then migrate
to omegasomes. There are diseases that are
thought to have their site of pathology at the
autophagy initiation step, although the exact
mechanisms have not yet been solved. Examples
of these are SENDA (static encephalopathy of
childhood with neurodegeneration in adulthood),
and Mitochondrial membrane protein-associated
neurodegeneration (MPAN). Lafora disease is
included here as it is correlated with LC3 deficits,
which occur before LC3-II formation.Mutations in WDR45, Encoding WIPI4 e
SENDA (Beta-Propeller Protein-
Associated Neurodegeneration (BPAN))
This is a disorder with brain iron accumulation
(NBIA) caused by mutations in WDR45, encoding a
protein called WIPI4 [80,81]. The disease has also
been called SENDA (static encephalopathy of child-
hood with neurodegeneration in adulthood). Children
show global developmental delay, then dystonia and
dementia in the teens. Cell studies show accumula-
tions of lipidated LC3, and increased levels of LC3
colocalising with mATG9, not usually seen on
mature autophagosomes [82]. This suggests that
mutations in WDR45 inhibit the development of the
autophagosome, which may be through the regula-
tion of the localisation of mATG9.Mitochondrial Membrane Protein-
Associated Neurodegeneration (MPAN)
In 2009, a family from Mali was identified with two
sisters affected by spastic paraplegia [83a, b]. These
patients had severe weakness of lower limbs butalso muscle atrophy of their upper limbs. Homo-
zygosity mapping localised the candidate gene
region to chromosome 19p 13.11-q12, defining this
as a distinct form of hereditary spastic paraplegia
with amyotrophy, designated SPG43. Four years
later, exome sequencing revealed a homozygous
missense variant in (c.187G > C; p.Ala63Pro) in
C19orf12, a gene implicated in neurodegeneration
with brain iron accumulation (NBIA) [84], and
identified as the cause of a distinct clinical subtype
of neurodegeneration with brain iron accumulation
two years previously [85]. NBIAs are a mixed set of
diseases that present with a gradual development of
extrapyramidal symptoms, together with basal gang-
lia deposition of iron. There are about nine genes
that are known to result in NBIA [86], each having
similar symptoms. The common clinical features of
NBIA are gradual development of dystonia, dysar-
thria, spasticity, and parkinsonism. Other features
may include optic atrophy leading to blindness,
retinal degeneration, and peripheral neuropathy.
Mitochondrial membrane protein-associated neuro-
degeneration (MPAN) is the third commonest NBIA
and is caused by mutations in the gene C19orf12
[85]. This disease has its onset in childhood, and
additional features may include a motor neuropathy
marked by a raised creatine kinase.
The function of the protein has not yet been fully
elucidated but has been proposed to have a role in
the regulation of autophagy at the sites of autopha-
gosome formation [87]. Overexpression of EGFP-
tagged wild type C19orf12 induced the conversion of
the autophagic marker LC3 heavy form (LC3I) to the
light form (LC3II) compared to cells transfected with
EGFP empty vector, and reduction of p62, indicating
the elevation of basal autophagy levels. In contrast,
the overexpression of the vectors carrying mutant
forms of the protein was unable to gain their correct
internal localisation and failed to promote autophagy
induction. As a result, basal autophagy activity was
stable despite treatment with oxidative stressors.Lafora Disease
Lafora Disease (LD) is a rare, autosomal reces-
sive, neurodegenerative disorder characterised by
myoclonic epilepsy, presenting between 8 and 18
years with tonic-clonic seizures, myoclonus, drop
attacks and visual hallucinations, rapidly leading to
cognitive decline with dementia, apraxia, aphasia,
and vision loss [88]. Most patients have mutations in
one of two genes, which are EPM2A, encoding a
protein phosphatase called Laforin, and EPM2B
(Malin), an E3 ubiquitin ligase [89]. In Lafora
disease, there are Lafora bodies (inclusion bodies)
that are found in the cytosol of neurons, and also in
the cytoplasm of cells from tissues with high
carbohydrate metabolism (liver, heart, skeletal
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polyglucosans, which are an abnormal, heavily
phosphorylated, and poorly branched form of
glycogen.
Laforin interacts with malin to form a complex; this
initiates ubiquitination and degradation of proteins
that function to regulate the synthesis of glycogen.
Laforin can also act as a glycogen phosphatase,
preventing glycogen from being phosphorylated.
This has the effect of stopping too much glycogen
from being phosphorylated. This is useful as it
inhibits the formation of glycogen polymers that are
prone to aggregation to form Lafora bodies. In the
related malin knockout mouse model, glycogen
accumulation was demonstrated and accounted for
the neurodegeneration and functional conse-
quences [90]. It should also be noted, however,
that defects in autophagosome formation have also
been demonstrated [90]. Human fibroblasts from LD
patients lacking laforin were found to have reduced
levels of LC3-II compared with healthy fibroblasts.
This was confirmed with mouse embryonic fibroblast
cells from laforin null mice and suggested that the
insufficiency of laforin-malin complexes will inhibit
the development of the autophagosome [91]. Treat-
ments have traditionally centred on antiepileptic
therapies. However, efforts are now turning to the
downregulation of brain glycogen synthesis and
disease gene replacement [92].Phagophore Membrane Elongation
Once the VPS34 complex has generated PI3P,
PI3P binding proteins, such as WIPI family proteins
are recruited [58]. Their target is a membrane
resident phospholipid (phosphatidylethanoloamine
(PE)). The conversion of soluble LC3-I to lipid-bound
LC3-II is an important step in the formation of
autophagosomes [28]. Single-gene defects that
affect the autophagy pathway at this stage include
some of the hereditary childhood ataxias, such as
that due to mutations in the ATG5 gene, as ATG5
deficiency can result in a defect in LC3 lipidation.Hereditary Childhood Ataxia due to
Mutations in ATG5
Ataxia is a rare disorder affecting balance and
coordination, so that affected patients find walking
difficult and suffer falls. This disease is associated
with abnormalities in the cerebellum and specifically
Purkinje cells. Children with ataxia may have
associated coordination problems and learning
difficulties. There are over 60 genes that areknown to cause ataxia. Two Turkish siblings who
presented with ataxia and developmental delay were
found to have a homozygous mutation in the gene
encoding ATG5 [93]. The reported E122D mutation
in ATG5 is thought to involve the ATG12-ATG5
interaction site. Disease affected patient cells
showed significantly reduced ATG12-ATG5 conju-
gate, raising the possibility that autophagy may be
impaired via inhibition of this conjugation. Perhaps
not surprisingly, these same mutant cells showed
reduced autophagic flux.Hereditary Spastic Paraplegia (SPG 49)
due to TECPR2 Mutations
Hereditary spastic paraplegias (HSPs) present
with increased tone and reduced muscle strength in
the lower limbs; and sometimes other complications,
such as ataxia, dementia, or amyotrophy. There
appears to be a degeneration of motor neurons
occurring in a retrograde fashion. There are more
than 70 genes known to cause this; one of these is
mutations in the gene encoding tectonin beta-
propeller repeat-containing protein 2 (TECPR2)
[94]. Affected patients have been reported with
learning difficulties, central hypoventilation, and
gastro-oesophageal reflux. TECPR2 is known to
interact with ATG8 and appears to work as a scaffold
for the COPII coat protein SEC24D [95]. The export
of cargo proteins from the endoplasmic reticulum
(ER) is mediated by COPII-coated vesicles that form
at endoplasmic reticulum exit sites (ERES). The
COPII components have isoforms: these may deliver
selection to the export of cargoes, particularly in
relation to SEC24. TECPR2 is thought to be
necessary for the proper working of ER exit sites
and export from the ER. This occurs with the
assistance of lipidated LC3C.
The ATG8 family of proteins is able to recruit
autophagy proteins containing domains that interact
with LC3. They further have a function in the
extension and closing of the phagophore membrane.
LC3 is also needed to bring labelled cargo into
autophagosomes via LC3 interaction region cargo
receptors. The autophagosomal membrane elon-
gates by appropriating other cellular membranes,
such as the plasma membrane, mitochondrial,
recycling endosomes, and the Golgi complex [28].
Vesicles that contain ATG proteins are involved in
delivering some of the membranes. The membrane
of the autophagosome finally becomes continuous,
creating a bi-layered vesicle. The next step is the
removal of the ATG proteins, which matures
(including stripping of the ATG proteins), before
fusing with a lysosome. During this process, coat
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membranes with their cargo. ATG9 is a specific
cargo of adaptor protein-4 [96]. Adaptor protein-4
promotes signal-mediated export of ATG9A from the
trans-Golgi network to the peripheral cytoplasm,
contributing to lipidation of LC3B and maturation of
preautophagosomal structures.Hereditary Spastic Paraplegia due to
Adaptor Protein-4 Deficiency
This disease presents with many of the features of
hereditary spastic paraplegia, as already outlined
previously. It is caused by mutations in genes that
encode subunits of adaptor-protein 4 (SPG47,
SPG52) [97]. Additional features of patients include
early floppiness that graduates to stiffness, learning
difficulties, and reduced brain volume, thin corpus
callosum, and seizures. The pathology is poorly
understood, but mouse models show many of the
neurological features of patients and show ATG9
mislocalisation; ATG9 shows expression throughout
the trans-Golgi network and reduced expression in
peripheral cytoplasm. There appears to be an
accumulation of toxic proteins in neurons. Impaired
autophagic degradation of protein aggregates is
likely to contribute to the neuroaxonal dystrophy in
this disease.Diseases Affecting Cargo Recognition
or Delivery for Degradation
Selective autophagy is achieved by labelling of
cargo by ubiquitin chains, recognised by autophagy
receptors. These connect autophagic cargo to the
autophagosome membrane through their LC3-inter-
actions. ULK1 is activated independently of mTOR,
and there is some evidence that huntingtin, the wild
type protein product of the Huntingtin gene, may be
the molecular link [98]. Huntingtin may also mediate
the interaction of p62 and LC3 with ubiquitin
polypeptides. This links the recognition of cargo
with selective autophagy [28].p62 Mutations
It has been estimated that 30% of newly made
proteins are misfolded in health [1]. The ubiquitin-
proteosome system (UPS) and the autophagy path-
way are recognised to maintain homeostasis in cells.
Although distinct, the proteolytic pathways interact
and are important for the survival of cells both in
health and stress [99]. There are shared proteins,
including HttQ74 and SQSTM1/p62. This is a
classical receptor of autophagy and important for
ubiquitinated protein degradation. SQSTM1/p62 is ascaffold protein, and functions to anchor the ubiqui-
tinated proteins to the autophagosome membrane,
promoting degradation of unwanted molecules [100].
Mutations in SQSTM1/p62 are found in frontotem-
poral dementia (FTD) and amyotrophic lateral
sclerosis in adults (ALS) [101]. However, recently,
biallelic loss-of-function variants were identified in
SQSTM1/p62 in nine affected individuals from four
families with childhood- or adolescence-onset neu-
rodegenerative disorder characterised by gait
abnormalities, ataxia, dysarthria, dystonia, vertical
gaze palsy, and cognitive decline [102]. They
reported evidence of a defect in the early response
to mitochondrial depolarisation and autophagosome
formation. In a study of fibroblasts from FTD patients
carrying two independent pathogenic mutations in
the p62 gene, p62 deficiency was found to be
associated with inhibited complex I mitochondrial
respiration due to lack of NADH for the electron
transport chain [103]. These findings highlight the
implication of energy metabolism in pathophysiolo-
gical events associated with p62 deficiency.Huntington Disease
Huntington disease (HD) is a progressive, neuro-
degenerative disorder that causes uncontrolled
movements, emotional problems, and loss of think-
ing ability (cognition). It is estimated to affect
between 3 and 7 per 100,000 people of European
ancestry and is less common in people of Japanese,
Chinese, and African descent. The most common
form is an adult onset, but there is a juvenile form that
begins in childhood or adolescence. In addition to
the features listed above, it also causes slow
movements, clumsiness, frequent falls, rigidity,
slurred speech, and drooling. School performance
declines as thinking and reasoning abilities become
impaired. Seizures occur in 30e50% of children with
this condition. Disease progression is usually faster
in childhood-onset compared with adult-onset
disease.
This is an autosomal dominant trinucleotide repeat
disorder, caused by N-terminal polyglutamine tract
expansions (blocks of cytosine-adenine-guanine
trinucleotides in various multiples of repeats). The
trinucleotide usually may show multiples up to
10e35 times. However, patients with Huntington
disease may show many more repeats, and there
appears to be an inverse relationship between the
number of tandem repeats and the age of onset; the
childhood-onset forms of the disease have the
highest number of repeats. There is some evidence
that the predominant action of the HD mutation is a
toxic gain of function [104]. Until recently, there has
been no disease-modifying therapy available for HD.
Various steps in the autophagy pathway are
altered in HD [105]. These include a defect in
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decreased fusion between autophagosomes and
lysosomes, leading to a build-up of toxic materials in
the cytoplasm and empty autophagosomes. The
primary defect may be in the ability of autophagic
vacuoles to recognise cytosolic cargo in HD cells
[106]. Autophagosomes fail to efficiently trap cyto-
solic cargo in their lumen. This failure to properly
engulf polyglutamine tract aggregates, or inefficient
cargo loading, leads to slower turnover, decay, and
accumulation inside HD cells.
Wild-type huntingtin regulates autophagy by bind-
ing and releasing ULK1 from mTOR and supporting
the p62 adaptor interaction with LC3108. Mutated
huntingtin, on the other hand, forms aggregates and
is likely toxic, but can be cleared by autophagy. In
HD cells containing polyglutamine aggregates,
these aggregates sequester mTOR, resulting in
decreased mTOR activity and an increase in
autophagy, leading to more rapid clearance of the
soluble protein in such cells [104]. In contrast, cells
expressing nonaggregated mutant polyglutamine
proteins seem to correlate with greater toxicity and
autophagy inhibition. The soluble mutant huntingtin
protein competes with the deubiquitinating enzyme
Ataxin-3, which is protective, for Beclin-1 interaction.
This competitive binding inhibits autophagy, and
reduced expression of LC3 and Beclin-1 have been
found in protein extracts from brain samples of
patients with HD [107].
Rapamycin, an autophagy inducer, has been
shown to enhance mutant huntingtin fragment
clearance and attenuate toxicity, and in fact, may
have wider applications for enhancing the autopha-
gic clearance of a variety of proteins and reduces
their toxicity [108]. A recent early-phase trial of an
antisense oligonucleotide designed to inhibit HTT
mRNA has demonstrated reductions of mutant
huntingtin in human patients and holds promise for
future treatments for this devastating disease [109].Autophagosome Maturation and Fusion
with Lysosomes
Once the autophagosomal membrane has formed
a bi-layered vesicle (autophagosome), the ATG9
proteins are stripped out before fusion with the
lysosome. Before that can occur, machinery has to
be recruited that will approximate the lysosomes
(microtubule-based kinesin motors), and that will
fuse the autophagosome with the lysosome [28].
This machinery includes SNAREs (syntaxin 17 and
synaptosomal-associated protein 29 (SNAP29) on
the autophagosome, vesicle-associated membrane
protein 8 (VAMP8) on the lysosome, and the
homotypic protein fusion and sorting (HOPS) com-
plex, which mediates membrane tethering to support
SNARE-mediated fusion. Disorders of the pathwaythought to be at this stage include a rare form of
leukoencephalopathy, and VICI syndrome.Leukoencephalopathies
Leukoencephalopathy refers to diseases affecting
the white matter of the brain. White matter consists
mainly of myelinated axons that carry the nerve
impulses between the neuronal cell bodies in the
gray matter. White matter disease affects the
networking between neuronal cell body centres in
the gray matter. Myelin is disrupted, either through
destruction or from biochemically abnormal myelin
production. White matter disorders tend to present in
childhood rather than infancy, with initially normal
cognitive function. Demyelination may be early,
causing peripheral neuropathy, and spasticity may
be severe. Seizures tend to be a later feature. White
matter diseases may present with motor signs, such
as gait disturbance, ataxia, and spasticity, and with
optic atrophy and blindness. Among many causes,
rare monogenic defects in the autophagy pathway
include mutations in vacuolar sorting protein 11
(VPS11), needed for autophagosome membrane
fusion.
VPS11 protein, encoded by the VPS11 gene, is a
core component of homolytic fusion and protein
sorting (HOPS) and class C core vacuole/endosome
tethering (CORVET) protein complexes, involved in
membrane trafficking and fusion of the lysosomes
and endosomes [110]. The C846G SNF8 mutation
causes aberrant ubiquitination and accelerated turn-
over of VPS11 protein, as well as compromised
VPS11-VPS18 complex assembly. Reduced VPS11
expression causes impaired autophagic flux, which
impairs autophagy in human cells.VICI Syndrome
Mutations EPG5 cause VICI syndrome, an infancy
onset disorder [6]. The key clinical features include
underdevelopment of the corpus callosum, progres-
sively small head, cataracts, cardiomyopathy, immu-
nodeficiencies, hypopigmentation, and global delay.
Other important features include floppiness due to
muscle disease. There is evidence of Purkinje cell
loss and diffuse cerebral atrophy. This, together with
loss of previously acquired skills, points to neurode-
generation. Children succumb to heart failure and
infections. A large case series of 50 children from 30
families showed that neurodegeneration is a primary
effect of EPG5 mutation, not secondary to other
neurodevelopmental defects [111].
EPG5 is the human homologue of the metazoan-
specific autophagy gene epg-5, encoding a key
autophagy regulator (ectopic P-granules autophagy
protein 5), implicated in the formation of
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models resulted in a build-up of abnormal autolyso-
somes, suggesting that Epg5 is also involved in the
later stages of autophagy, including autophago-
some-lysosome fusion and proteolysis [113,114].
Investigation of muscle and skin samples from
affected patients showed a build-up of LC3-positive
autophagy vesicles and linking proteins NBR1 and
p62. This suggests defective autophagic flux at the
late stages of autophagy. The clearance of intracel-
lular pathogens is dependent on an intact autophagy
pathway [115], and the failure to do this is likely to
impair immunity and explain the recurrent infections
seen in patients.Hereditary Spastic Paraplegia due to
CCT5 Mutations
This is an autosomal recessive HSP, presenting
with a peripheral sensory deficit with generalised
weakness. The neuropathology involves posterior
column atrophy, and the disease is due to mutations
in CCT5 [116]. This disease was reported in a
Moroccan family where there were four siblings from
age 1e5 years, with a severe mutilating sensory
neuropathy with sensory paraplegia. These children
had spasticity of their legs, exaggerated reflexes,
loss of sensation in the distal parts of both upper and
lower limbs, and deep perforating ulcers of hands
and feet. Unfortunately, the sensory neuropathy was
rapidly progressive. Nerve conduction studies con-
firmed a sensory axonal neuropathy. This gene
encodes the epsilon subunit of the cytosolic chaper-
onin-containing t-complex 1. The complex consists
of two identical stacked rings; unfolded peptide
chains enter the central cavity of the complex and
are folded in an ATP-dependent manner. The
complex folds cytoskeletal proteins, such as actin
and tubulin, but also proteins required for autophagy.
Mutations in the gene encoding the CCT5 subunit,
lead to the accumulation and aggregation of
misfolded proteins required for autophagy machin-
ery [117]. CCT5 also supports the degradation of
autophagosomes by modulating lysosomal function.Ataxia due to SNX14 Mutations
Twelve families were described with ataxia, coarse
facial features, and intellectual disability, and in
addition, had cerebellar atrophy [118]. These
families were found to have truncating mutations of
sorting nexin 14 (SNX14), encoding a ubiquitously
expressed modular PX-domain-containing sorting
factor. SNX14 interacts with phosphatidylinositol
3,5-bisphosphate (PtdIns [3,5]P2) localising to late
endosomes/lysosomes, which contain PtdIns [3,5]
P2. Neural progenitor cells with SNX14 mutationsshowed engorged lysosomes and a slower autop-
hagosomal clearance rate on the induction of
starvation. The data suggest that without SNX14,
there is a disruption of autophagosome clearance
through impairment of the function of lysosomes.Charcot Marie Tooth Disease due to
Mutations in Dynamins
Charcot Marie Tooth (CMT), also known as
Hereditary Sensory and Motor Neuropathy
(HSMN), or peroneal muscular atrophy, is the
name given to a group of inherited conditions that
damage the peripheral nerves. Symptoms usually
appear between 5 and 15 years of age, although
they may be delayed until adulthood. They can
present with muscle weakness in the feet, ankles,
legs and hands, abnormal gait, either high arched or
very flat feet, and numbness in the feet, arms, and
hands. This is a progressive condition with nerve
loss, and affects about 1 in 2500 people.
CMT is caused by mutations in genes that produce
proteins involved in the structure and function of
either the peripheral nerve axon or the myelin
sheath. All the mutations affect the normal function-
ing of peripheral nerves, causing them to degen-
erate. Motor nerve degeneration causes muscle
weakness and atrophy in the extremities, and
sometimes this is accompanied by sensory nerve
degeneration, which causes reduced ability to feel
heat, cold, and pain.
Over 70 genes are known to cause this disease,
but at least 2 genes encode proteins involved in the
autophagy pathway. Mutations in dynamin 2 also
cause CMT associated with neutropenia and early-
onset cataracts, together with facial weakness and
ptosis. Dynamin is a 100 kDa GTPase involved in
membrane and cytoskeleton remodelling. In the
central nervous system, dynamin-2 has a role in
endocytosis at the post-synaptic membrane, in
neurosecretion, and in neural process extension.
Most of the dynamin-2 CMT-related mutations are
located in the N-terminal region of the pleckstrin
homology domain in a region that is involved in the
insertion of dynamin into lipid membranes, and some
have been shown to be unable to bind phospholi-
pids. The protein also appears to be important for
lysosomal/autolysosomal acidification. Loss of func-
tion mutations is associated with the accumulation of
immature autophagosomes [119].Spinal Muscular Atrophy due to
Mutations in DYNC1H1
Spinal muscular atrophy (SMA) is a genetic
disease with spinal cord motor neuronal degenera-
tion, leading to severe muscle weakness, particularly
2748 Autophagy in neurodegenerationof the lower limbs [120]. Affected children had a
waddling, wide-based gait from infancy, leading to
difficulty in running. The upper limbs were unaf-
fected, and the weakness in the lower limbs did not
seem to be progressive. The cause was identified as
mutations in Dynein cytoplasmic 1 heavy chain 1
(DYNC1H1). This gene encodes a critical subunit of
the cytoplasmic dynein complex. Dyneins are a
family of cytoskeletal motor proteins (ATPases) that
transport cellular cargos along with microtubular
networks. They are essential for intracellular motility,
such as retrograde axonal transport, protein sorting,
and redistribution of organelles, such as lysosomes.
A key role is in the autophagosome migration phase
of autophagosome-lysosome fusion: autophago-
somes migrate to the locations of lysosomes via
the microtubular network. Disruption of the dynein
protein likely reduces the intracellular transport of
autophagosomes, and also of other proteins, allow-
ing them to accumulate and form aggregates.Hereditary Spastic Paraplegia due to
Mutations in SPG11 and SPG15
As discussed above, hereditary spastic paraple-
gias (HSPs) are a heterogeneous group of inherited
neurodegenerative and neurodevelopmental disor-
ders characterised by retrograde neurodegeneration
of the longest corticospinal motor neurons. The
commonest clinical presentation is with spastic
paraparesis and urinary incontinence, which man-
ifest as lower-limb hypertonia, weakness, and
reduced vibration sense. There are at least 70
different genetic loci identified (SPF 1e72) [121].
However, the commonest genetic cause (70%) is
due to mutations in the genes encoding the proteins
SPG11 (SPG11) and SPG15 (ZFYVE26). These
cause progressive stiffness of the legs, develop-
mental delay, pigmentary retinopathy, and amyotro-
phy. SPG11 and SPG15 encode spatacsin and
spastizin, respectively, which are needed for lyso-
somal development. There is an interaction with the
AP5 complex, which is needed for late endosome
membrane sorting [122]. The AP5 complex is a
member of a family of heterotetrametic adaptor
proteins that associates with SPG11 and SPG15 to
form a coat-like complex, with AP5 involved in
protein sorting, SPG15 facilitating the docking of
the coat onto membranes by interacting with PI3P,
and SPG11 (possibly with SPG15) forming a
scaffold. The SPG protein spastizin is encoded by
the gene ZFYVE26 and colocalises with early
endosomes, the endoplasmic reticulum, microtu-
bules, and vesicles involved in protein trafficking.
Spastizin interacts with the autophagy-related Beclin
1-UVRAG-Rubicon complex, a protein required for
cytokinesis and autophagy [123]. In cells lacking
spastizin, there is an impairment of autophagosomematuration and an accumulation of immature autop-
hagosomes. These defects were also observed in
neuronal cells and may be responsible for the
thinning of the corpus callosum seen in many
patients.Current Challenges
One of the great challenges of the field is to
translate the rapid advances in our understanding of
autophagy, into treatments for children affected by
single-gene disorders. Dysfunctional autophagy has
been reported in almost all the neurodegenerative
diseases studied, including common adult disorders,
such as Alzheimer’s and Parkinson’s [30,124e126].
Common therapeutic strategies include the induction
of autophagy to restore proteostasis, regardless of
the nature of the different misfolded proteins or
aggregates in these disorders. Driving autophagic
flux is neuroprotective in several transgenic mouse
models of neurodegenerative diseases and other
neurological disorders [30,124,125,127]. For exam-
ple, genetic and pharmacological enhancement of
autophagy was able to reduce the number of
synuclein aggregates, oxidative damage, and
improve neuronal viability [124,125,128]. Likewise,
pharmacological inducers of autophagy could
enhance the clearance of mutant huntingtin and
ameliorate the disease phenotypes in mouse models
of HD [30,124,125,127,129,130].
In spite of the robust literature on the role of
autophagy in neurodegenerative disease, a lack of
clinically relevant data for autophagy inducers has
hampered clinical trial efforts. Moreover, emerging
studies indicate the autophagy modulators can have
cell-type-specific action and efficacy [131], and there
is no clear information about the nature of the
candidate autophagy-inducing drug for clinical trans-
lation. It is highly unlikely that pharmaceutical
companies will invest in separate clinical trials for
the 150 or so rare childhood-onset neurodegenera-
tive disorders. There is, therefore, a need to develop
potent autophagy inducers as a shared mechanism
in order to restore functional autophagy and improve
neuronal viability across several rare neurodegen-
erative diseases.
There are over 20 FDA-approved drugs known to
induce autophagy, and that cross the blood-brain
barrier. These are drugs that are licensed for use in
other conditions, but that also have known autop-
hagy-inducing properties. There are no obvious
side-effects that are known from the therapeutic
stimulation of autophagy in neurodegenerative dis-
eases where activation of autophagy acts as a
protective pathway. One theoretical concern is that
stimulation of autophagy could decrease the levels
of mitochondria (via mitophagy), and affect respira-
tion. However, this scenario has never been seen in
2749Autophagy in neurodegenerationtransgenic mice or patients because the mitochon-
drial load has to be significantly lowered by 75% in
order to have an impact on respiration [104,127].
Any focus on repurposed drugs will probably have to
investigate a mTORC1-independent mechanism
rather than those agents that inhibit mTORC1,
such as rapamycin. This aspect is particularly
important and clinically relevant for long-term drug
administration in neurodegenerative disease
patients because mTORC1 governs critical cellular
functions, such as cell growth and translation. The
mTORC inhibitors, therefore, may not be practical
solutions for inducing autophagy long-term.
For diseases where there is an accumulation of
toxic aggregates due to the gain of function
mechanisms, another approach is to target the
causative gene with antisense therapy. The current
example of this approach is in Huntington disease,
where a CAG nucleotide repeat expansion in the
huntingtin gene results in the production and
accumulation of mutant protein. Recently, the results
of treatment with an antisense oligonucleotide have
been published, designed to reduce concentrations
of huntingtin mRNA [109]. Intrathecal administration
to patients with Huntington’s disease was shown to
be safe, with dose-dependent reductions in mutant
huntingtin. This is a really exciting approach that is
likely to be generalisable to other autophagy defects
caused by gain of function mechanisms.
Finally, gene replacement therapy is gaining
interest as an option for single-gene disorders,
causing a deficiency in an essential protein for the
autophagy pathway. Gene therapy that delivers a
working version of a gene would be an attractive
strategic approach to some of these diseases, such
as Lafora disease [92]. The most popular strategy
that has been developed to introduce a transgene is
the use of the viral vector adeno-associated virus.
This is the vector of choice as it is nonpathogenic, is
long-lasting so that only one treatment might be
needed, and crosses the blood-brain barrier, making
intravenous delivery possible, although intrathecal
delivery is likely to be a preferred route. Any gene
therapy to arrest neurodegeneration would need to
be delivered before extensive central nervous
system damage has occurred.Acknowledgements
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